With proof of concept that outstanding remissions can be achieved in select AML patients receiving low-intensity therapy, investigators are now looking to combine oral decitabine/cedazuridine with other novel agents such as isosorbide dehydrogenase (IDH)1/2 inhibitors, fms-like tyrosine kinase 3 (FLT3) inhibitors, menin inhibitors, or other agents, with or without the use of venetoclax to improve outcomes for all AML patients. This evidence concerns the gene FLT3 and acute myeloid leukemia.